In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Bruno Quinney talks to Dr Mrinal Kammili, Head… Read More
Dr Kenneth Barr, Head of Strategic Collaborations at Syngene, explores how early-phase drug development is moving towards integrated translational strategies. Drug development continues to grow in complexity, risk, and cost. With timelines stretching over a decade and the average spend per new drug exceeding $2.6 billion, many… Read More
DDW has added Fatah Kashanchi, PhD, Professor, George Mason University and Heather Branscome, MS, PhD, Senior Scientist, ATCC to its track, Concept to Cure: Curiosity and Lab Automation in Drug Discovery at SLAS2025 (25-29 January 2025, San Diego, USA). Heather Branscome Fatah Kashanchi This free programme, which… Read More
The latest speaker to the DDW SLAS track is Alexander G Godfrey, Automation Consultant, ASPIRE Scientific Lead, National Center for Advancing Translational Sciences (NCATS). Alexander G Godfrey Godfrey will be speaking at DDW‘s track – Concept to Cure: Curiosity and Lab Automation in Drug Discovery at SLAS2025 (25-29 January… Read More
By Ibis Sanchez-Serrano and Rathnam Chaguturu Mitigation of COVID-19 pandemic requires a combination of effective epidemiological policies and the discovery/development of powerful drugs against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes this disease. This article examines the major initiatives being explored at the… Read More
Honing in on perfect targeting By Dr Samantha Zaroff Volume 21 Issue 3 – Summer 2020 The pros and cons of different delivery modalities for personalised cancer vaccines. Introducing neoantigens directly into a patient in order to elicit an anti-tumour killing immune response is known… Read More
The CELL CULTURE innovations increasing drug discovery success By Helen Stewart-Miller and Abby George Volume 21 Issue 3 – Summer 2020 ‘Fail early, fail fast’ has been a mantra in the pharmaceutical industry for several years and directly impacts the overall strategy of many drug discovery and development… Read More
Collaborative Research Leads To New Understanding Of Biomarkers By Dr Max Ryadnov and Professor Jason Crain A new collaborative research paper sheds light on the way antibodies distinguish between different but closely related ‘biomarkers’ – in this case protein fragments which reveal information about the condition of the… Read More
Leading in vivo pharmacology and consultancy services firm RenaSci, part of the Sygnature Group, have bolstered their Kidney Disease and Fibrosis capabilities with the appointment of Dr Wioletta Pijacka. Wioletta is an in vivo translational biologist with over 12 years of experience in renal and cardio-vascular… Read More
Newly developed recombinant antigens derived specifically from 2019-nCoV for use in infectious disease research, and assay and vaccine development. The Native Antigen Company, one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced… Read More
The financing will accelerate the development of first-in-class therapies in autoimmune disease and immuno-oncology. Pathios Therapeutics Limited (“Pathios”), an innovative biotech company focused on the development of first-in-class therapies for autoimmune diseases and cancer, today announced a US$8.8M Series A financing round with leading international healthcare… Read More
A team of British and American scientists has discovered a way to slow the growth of breast cancer stem cells in the lab. The study led by Dr Bruno Simões and Professor Rob Clarke from The University of Manchester could eventually lead to combination drug therapies on previously… Read More
Image: Joshua Coleman According to the Department of Health and Social Care (DHSC), pharmaceutical companies should stockpile six weeks’ worth of goods “to help ensure the continuity of supply of medical goods into and out of the UK”. In a letter to the industry Steve Oldfield, Chief Commercial Officer,… Read More
Image: Ani Kolleshi The US Department of Defence (DOD) has awarded Evotec’s Seattle-based subsidiary, Just-Evotec Biologics a contract worth $18.2 million to develop monoclonal antibodies (mAbs) for treatment and/or prevention of COVID-19 Under the contract, Just–Evotec Biologics will design a manufacturing process for the production of Current Good… Read More
Some of the most promising advances in cancer treatment have centred on immunotherapies that rev up a patient’s immune system to attack cancer. However, immunotherapies don’t work in all patients, and researchers have been searching for ways to increase their effectiveness. Now, researchers at Washington University School of… Read More
British Patient Capital is committing $65m to SV Health Investors’ latest fund, SV7 Impact Medicine Fund (IMF), to turn scientific breakthroughs into biotech companies producing high impact precision medicine drugs for poorly treated diseases. The commitment increases British Patient Capital’s exposure to life sciences and health technology, building… Read More
